Krystal Biotech Inc. (KRYS) shares plummeted 5.27% during intraday trading on Monday, reversing earlier pre-market gains.
The biopharmaceutical company reported first-quarter 2026 earnings that exceeded analyst expectations, with adjusted EPS of $1.83 beating the mean estimate of $1.42 and revenue of $116.36 million surpassing the $112.13 million forecast.
However, the stock's decline may be attributed to concerns highlighted in the earnings report, which noted that the mean earnings estimate of analysts had fallen by about 2.5% over the last three months, with two analysts negatively revising their estimates in the past 30 days.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.